NeuroSense Reports Positive Biomarker Data for PrimeC in Alzheimer's

The RoAD study, a randomized, double-blind, placebo-controlled trial, involved eight participants to evaluate the safety and biological impact of PrimeC. Among those enrolled, three patients provided complete CSF and plasma samples over a 12-month period. Analysis revealed shifts in hallmark Alzheimer's indicators, including tau proteins and the amyloid-beta 42/40 ratio. Furthermore, the study identified changes in alpha-synuclein and TDP-43, proteins often associated with faster dementia progression when present alongside Alzheimer's pathology.

NeuroSense CEO Alon Ben-Noon described the results as a preliminary signal that PrimeC’s multi-target mechanism—already under investigation for ALS—may address biological drivers central to Alzheimer's. While the company acknowledges the study's limited scope, these findings provide a foundation for designing a larger, more robust clinical trial. Prof. Steven E. Arnold of Harvard Medical School noted that the observed proteostatic effects align with the drug's proposed mechanism, though he emphasized the necessity of future testing to determine if these biological changes translate into actual clinical benefits for patients.